2016, Vol. 4, Issue 6, Part B

author(s)
Elizabeth Alejandrina Guzmán Hernández, David Segura-Cobos and Pedro López-Sánchez

abstract
Metabolic syndrome represents one of the major risk factors for developing cardiovascular disease, with high risk affecting most of the worldwide adult population in both sexes. In Mexico, cardiovascular diseases are the first cause of morbidity and mortality. Generally, for the therapeutic management of both diseases is using multiple drugs with different mechanisms of action, which aim to reduce risk factors, associated with metabolic syndrome. These are managed for a long time, which often represents a high economic cost. On the other hand, some patients have no adherence to treatment as this one, is ineffective, the adverse effects are situations that require change or discontinue medication immediately.